pyrimidin-2-one beta-ribofuranoside has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deptuła, M; Kamińska, J; Pikuła, M; Rodziewicz-Motowidło, S; Sachadyn, P; Sass, P; Skoniecka, A; Sosnowski, P; Zieliński, J | 1 |
| Ericsson, P; Förnvik, K; Jansson, L; Nittby, H; Salford, LG; Sjögren, HO; Skagerberg, G; Strömblad, S; Widegren, B; Xue, Z | 1 |
2 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Alloxan Diabetes
| Article | Year |
|---|---|
Examination of epigenetic inhibitor zebularine in treatment of skin wounds in healthy and diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Epigenesis, Genetic; Mice; Skin; Wound Healing | 2022 |
Zebularine induces long-term survival of pancreatic islet allotransplants in streptozotocin treated diabetic rats.
Topics: Animals; Blood Glucose; Cytidine; Diabetes Mellitus, Experimental; Gene Expression Regulation, Enzymologic; Graft Survival; Indoleamine-Pyrrole 2,3,-Dioxygenase; Islets of Langerhans Transplantation; Male; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Time Factors; Transplantation, Homologous; Treatment Outcome | 2013 |